Leukaemia Section
Mini Review

\(t(2;7)(p11;q21), t(7;14)(q21;q32) \text{ CDK6/IgH, } t(7;22)(q21;q11)\)

Jean-Loup Huret

Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France (JLH)

Published in Atlas Database: February 2009
Online updated version: http://AtlasGeneticsOncology.org/Anomalies/t0714q21q32ID1361.html
DOI: 10.4267/2042/44666

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.

© 2010 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Identity

Note
The translocation \(t(7;14)(q21;q32)\) herein described must not be confused with the \(t(7;14)(q21;q32)\) with ERVWE1/IgH involvement, seen in chronic lymphocytic leukaemia (Wahbi et al., 1997). There is also a case of acute myeloid leukaemia with \(t(7;14)(q21;q32)\) in a female patient, with no other data (Stephenson et al., 1995).

Clinics and pathology

Disease
Chronic lymphocytic leukaemia (CLL) and splenic marginal zone lymphoma (SMZL) (Corcoran et al., 1999; Hayette et al., 2003).

Phenotype/cell stem origin
Six patients, aged 52–79 years, 5 male / 1 female cases.

Prognosis
Survival data was: 3 years+, 6 years+, and a case dead 16 years after diagnosis in the CLL cases; 4 years+, 5 years+, and 8 years+ in the SMZL and variants cases.

Cytogenetics

Cytogenetics morphological
Sole anomaly in two of six cases.

Additional anomalies
Accompanied with +12 in two CLL cases, del(13q) in one CLL, del(7q) in one SMZL case.

Genes involved and proteins

CDK6
Location
7q21.2
Protein
G1 phase kinase; phosphorylates RB1 but with a distinct activity from CDK4. Control of the cell cycle; blockage of differenciation (Grossel and Hinds, 2006).

IGH
Location
14q32.33
Protein
Immunoglobulin heavy chain (see Lefranc, 2003).

Result of the chromosomal anomaly

Hybrid gene
Description
Translocation of CDK6 close to enhancers constitutively active in B- cells.

Fusion protein
Note
The case elsewhere reported with \(t(7;14)(q21;q32)\) ERVWE1/IgH (Wahbi et al., 1997) may also involve
CDK6 instead of ERVWE1, as it is known that IG enhancers may act at long distance. However, the breakpoint in this latter case was found 94 bases upstream ERVWE1. ERVWE1 is 127 kb upstream CDK6 on minus strand of the DNA (ERVWE1 is from 91 935 631 to 91 945 186, and CDK6 from 92 072 173 to 92 303 877), while the breakpoints herein reported are situated within 2 to 66 kb near CDK6, and they appear to be telomeric to CDK6.

**Oncogenesis**

Overexpression of CDK6 was demonstrated (Hayette et al., 2003).

**References**


---

This article should be referenced as such: